Join the Lidocaine group to help and get support from people like you.
Lidocaine News
Related terms: Lidocaine Topical, Lidocaine Ophthalmic
High-Strength Lidocaine Skin Creams Can Cause Seizures, Heart Trouble, FDA Warns
FRIDAY, March 29, 2024 – Some pain-relieving skin products contain potentially harmful doses of the numbing agent lidocaine and should be avoided, the U.S. Food and Drug Administration warns. These...
FDA Medwatch Alert: FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects
March 26, 2024 – The U.S. Food and Drug Administration is warning consumers not to use certain over-the-counter analgesic (pain relief) products that are marketed for topical use to relieve pain...
FDA Medwatch Alert: Hospira, Inc. Issues a Voluntary Nationwide Recall for Sodium Bicarbonate Injection and Lidocaine HCl Injection Due to the Potential for Presence of Glass Particulate Matter
October 2, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10mL vial; 1% Lidocaine...
FDA Medwatch Alert: Teligent Pharma, Inc. Issues Worldwide Voluntary Recall of Lidocaine HCl Topical Solution USP 4% Due to Super Potency
07 December 2021 – Buena, NJ, Teligent Pharma, Inc. is voluntarily recalling two lots of Lidocaine HCl Topical Solution USP 4%, 50ml in a screw cap glass bottle listed in the table below to the user l...
FDA Medwatch Alert: Edge Pharma, LLC Issues Voluntary Nationwide Recall of All Drug Products Due to Lack of Sterility Assurance
December 4, 2021 – Colchester, VT, Edge Pharma, LLC is voluntarily recalling all lots of all drugs compounded at Edge Pharma, LLC to the consumer level. All products are being recalled due to process ...
FDA Medwatch Alert: Teligent Pharma, Inc.’s Issues Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4% Due to Super Potency
October 12, 2021 – Buena, NJ, Teligent Pharma, Inc. is voluntarily recalling the five lots of Lidocaine HCl Topical Solution 4%, 50mL in a screw cap glass bottle listed in the table below to the...
FDA Medwatch Alert: Hospira Recalls 0.5% Bupivacaine Injection and 1% Lidocaine Injection, Due to Mislabeling
Hospira, Inc., a Pfizer company, is voluntarily recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCl Injection, USP 30 mL, to the...
Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from t...
FDA Medwatch Alert: Lidocaine HCI Injection, USP 10 MG Per ML, 30 ML Single-Dose, Preservative-Free, by Hospira: Recall - Particulate Matter
ISSUE: Hospira announced it will initiate a voluntary recall of one lot of 1% Lidocaine HCI for Injection, USP, 10 mg per mL, 30 mL Single-dose, Preservative-Free to the user level due to a confirmed...
FDA Medwatch Alert: Lidocaine HCl Injection, USP, 2 percent, by Hospira: Recall - Visible Particulates
ISSUE: Hospira, Inc. is recalling one lot of Lidocaine HCl Injection, USP, 2%, 20 mg per mL, 5 mL single-Dose Vial, Preservative-Free (NDC 0409-2066-05; Lot 25-550-DD, Expiry 1JAN2015) to the user...
FDA Medwatch Alert: Lidocaine HCl Injection 2%, 5 ml Vial by Hospira: Recall - Presence of Particulate Matter
ISSUE: Hospira initiated a voluntary nationwide recall to the user level for one lot of Lidocaine HCl Injection, USP, 2%, 5 mL Single-Dose Vial (NDC 0409-2066-05), Lot 32-135-DD, expiration date...
FDA Medwatch Alert: Hospira brand Lidocaine and Marcaine: Recall - Presence Of Particulate
UPDATED 10/21/2013 with related product recall information Hospira announced a voluntary nationwide recall to the user level for one lot of 0.25% Marcaine (Bupivacaine HCl Injection, USP), 75 mg/30...
FDA Medwatch Alert: 1% Lidocaine HCl Injection By Hospira: Recall - Presence Of Dark Particulate
ISSUE: Hospira, Inc. announced it has initiated a voluntary nationwide recall of one lot of 1% Lidocaine HCI Injection, USP, 10 mg/mL, 20 mL Multiple-dose Fliptop Vial, NDC 0409-4276-01 Lot 25-090-DK ...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Burning Mouth Syndrome, Anesthesia, Arrhythmia